CDX 014Alternative Names: CDX-014; CR 014-vcMMAE
Latest Information Update: 26 Jul 2016
At a glance
- Originator Amgen; CuraGen Corporation
- Developer Celldex Therapeutics Inc
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Membrane protein inhibitors; T cell activation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Renal cell carcinoma